MarketCapExport financials
Acasti Pharma (ACST)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Acasti Pharma Balance Sheet 2026-2011 | ACST
Brief overview of Acasti Pharma 's balance sheet structure
Balance sheet changes are traced across five available annual reports between 2022 and 2026.
Assets fell from $128.6 million to $66.7 million. This may reflect either deliberate optimization or a reduction in business scale.
Assets outpaced liabilities, -48.2% versus -86.4%. Dependence on external funding declined.
Equity funds 95.9% of assets versus 84.2% initially. This creates a conservative balance sheet structure.
The cash share moved from 23.6% to 25.5%. A higher figure generally provides more room in an adverse scenario.
Retained earnings are negative at -$228.5 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Conclusion
Acasti Pharma retains a reasonably healthy balance sheet structure, which still needs support from earnings and cash flow.
Annual Balance Sheet Acasti Pharma
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -27.4 M | -30 M | - | - | -15.5 M | -5.12 M | - | -2.23 M | -1.05 M | -607 K | -1.17 M | -1.6 M | -329 K |
Long Term Debt |
- | - | - | 410 K | 191 K | - | - | - | 1.25 M | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | 75 K | 104 K | 86 K | 76 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | 12.2 M | 6.22 M | - | 115 K | 1.88 M | 10 M | - | - | 4.27 M |
Total Current Liabilities |
2.15 M | 1.93 M | 1.68 M | 3.41 M | 3.26 M | 1.58 M | 7.4 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.76 M | 5.38 M | 11.6 M | 11.2 M | 20.4 M | 6.8 M | - | 25.8 M | 11.4 M | - | 957 K | 3.18 M | 11.1 M | 2.39 M | 1.27 M | 5.24 M |
Retained Earnings |
-228 M | -221 M | -211 M | -198 M | -156 M | -146 M | - | -92.8 M | -56 M | - | -29.2 M | -26.6 M | -28.5 M | -19.6 M | -13.2 M | -14.3 M |
Total Assets |
66.7 M | 72 M | 73.3 M | 79.1 M | 129 M | 62.5 M | 14 K | 36.3 M | 17.8 M | - | 21 M | 29.7 M | 41 M | 11.9 M | 15.8 M | 3.4 M |
Cash and Cash Equivalents |
17 M | 22.1 M | 23 M | 27.9 M | 30.3 M | 50.9 M | 14.2 M | - | - | - | - | - | - | - | - | - |
Book Value |
63.9 M | 66.6 M | 61.7 M | 68 M | 108 M | 55.7 M | 14 K | 10.5 M | 6.37 M | - | 20.1 M | 26.6 M | 29.9 M | 9.5 M | 14.6 M | -1.84 M |
Total Shareholders Equity |
63.9 M | 66.6 M | 61.7 M | 68 M | 108 M | 55.7 M | 13 M | 11 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Acasti Pharma
| 2027-Q1 | 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 410 K | 430 K | 450 K | 174 K | 191 K | - | - | - | - | - | 38 K | 56 K | 71 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.76 M | 5.38 M | 3.6 M | 3.76 M | 6.26 M | 3.6 M | 3.76 M | 6.26 M | 5.38 M | 9.08 M | 9.22 M | 10.4 M | 11.6 M | 11.5 M | 11.5 M | 9.02 M | 11.2 M | 20.1 M | 20.7 M | 20.5 M | 20.4 M | 3.16 M | 5.59 M | 7 M | 6.8 M | 4.59 M | 4.96 M | 9.11 M | 9.86 M | - | - | - | 25.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-228 M | -221 M | -227 M | -225 M | -224 M | -227 M | -225 M | -224 M | -221 M | -221 M | -217 M | -214 M | -211 M | -208 M | -206 M | -202 M | -198 M | -169 M | -165 M | -160 M | -156 M | -152 M | -148 M | -149 M | -146 M | -140 M | -137 M | -131 M | -126 M | - | - | - | -101 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
66.7 M | 72 M | 68.5 M | 66.6 M | 69.8 M | 68.5 M | 66.6 M | 69.8 M | 72 M | 61.2 M | 65.3 M | 69.7 M | 73.3 M | 76.2 M | 78.2 M | 73 M | 79.1 M | 117 M | 121 M | 125 M | 129 M | 114 M | 120 M | 60.5 M | 62.5 M | 30.3 M | 13.8 M | 20.1 M | 22.9 M | - | - | - | 36.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
22.1 M | 23 M | 18.7 M | 16.9 M | 20 M | 18.7 M | 16.9 M | 20 M | 22.1 M | 836 K | 1.02 M | 3.04 M | 23 M | 2.06 M | 10.6 M | 5.41 M | 27.9 M | 26.2 M | 34.9 M | 38.4 M | 30.3 M | 33 M | 36.9 M | 41 M | 50.9 M | 26.5 M | 11.6 M | 12.1 M | 14.2 M | 16.9 M | 2.62 M | 1.11 M | 16.9 M | 6.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
63.9 M | 66.6 M | 64.9 M | 62.8 M | 63.6 M | 64.9 M | 62.8 M | 63.6 M | 66.6 M | 52.1 M | 56.1 M | 59.4 M | 61.7 M | 64.7 M | 66.7 M | 64 M | 68 M | 96.7 M | 100 M | 104 M | 108 M | 111 M | 114 M | 53.5 M | 55.7 M | 25.7 M | 8.87 M | 11 M | 13 M | - | - | - | 11 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
66.6 M | 61.7 M | 64.9 M | 62.8 M | 63.6 M | 64.9 M | 62.8 M | 63.6 M | 66.6 M | 52.1 M | 56.1 M | 59.4 M | 61.7 M | 64.7 M | 66.7 M | 64 M | 68 M | 96.7 M | 100 M | 104 M | 108 M | 111 M | 114 M | 53.5 M | 55.7 M | 25.7 M | 25.7 M | 8.87 M | 11 M | -4.29 M | -759 K | 3.28 M | 11 M | - | - | - | 7.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Acasti Pharma , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Aprea Therapeutics
APRE
|
$ 0.75 | 0.16 % | $ 4.9 M |  USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.82 | 0.54 % | $ 574 K | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.63 | 0.11 % | $ 495 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 13.69 | 0.36 % | $ 375 M |  Israel |
 |
Ardelyx
ARDX
|
$ 3.42 | 0.88 % | $ 824 M | USA |
 |
argenx SE
ARGX
|
$ 958.91 | 1.33 % | $ 58.8 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
$ 3.67 | 2.23 % | $ 133 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 26.43 | 0.09 % | $ 3.36 B | USA |
 |
Artelo Biosciences
ARTL
|
$ 4.04 | 1.11 % | $ 764 K | USA |
 |
Arvinas
ARVN
|
$ 7.74 | 3.13 % | $ 549 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 65.45 | 1.21 % | $ 8.75 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 23.49 | 0.04 % | $ 263 M | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 227.83 | 0.5 % | $ 13.8 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.65 | 1.09 % | $ 23.3 B |  Australia |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.12 | 0.88 % | $ 34.9 M | USA |
 |
Atossa Therapeutics
ATOS
|
$ 1.95 | 1.51 % | $ 16.8 M | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 8.5 | 5.59 % | $ 107 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.2 | 0.49 % | $ 2.18 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.94 | 4.3 % | $ 516 M |  Britain |
 |
Atea Pharmaceuticals
AVIR
|
$ 5.21 | 0.58 % | $ 425 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
$ 2.02 | 0.43 % | $ 172 M | USA |
 |
Axon Enterprise
AXON
|
$ 422.52 | 0.7 % | $ 33 B | USA |
 |
Axsome Therapeutics
AXSM
|
$ 184.39 | 0.73 % | $ 9.17 B | USA |
 |
Aytu BioScience
AYTU
|
$ 2.14 | 1.38 % | $ 26.4 M | USA |
 |
BridgeBio Pharma
BBIO
|
$ 65.8 | 0.34 % | $ 12.6 B | USA |
 |
BioCardia
BCDA
|
$ 1.01 | 0.96 % | $ 6.73 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 8.33 | 0.73 % | $ 1.75 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.68 | 0.82 % | $ 255 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
$ 1.89 | 0.8 % | $ 107 M | USA |
 |
Beam Therapeutics
BEAM
|
$ 24.45 | 0.37 % | $ 2.42 B | USA |
 |
Biogen
BIIB
|
$ 225.88 | 0.15 % | $ 33.1 B | USA |
 |
BioVie
BIVI
|
$ 1.52 | 1.95 % | $ 2.25 M | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 2.32 | 2.67 % | $ 5.72 B | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
$ 60.0 | 0.22 % | $ 11.5 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
$ 62.4 | 0.19 % | $ 127 B | USA |
 |
Benitec Biopharma
BNTC
|
$ 10.0 | 2.56 % | $ 466 M | USA |
 |
BioNTech SE
BNTX
|
$ 98.3 | 0.02 % | $ 23.8 B |  Germany |
 |
Burford Capital Limited
BUR
|
$ 3.92 | 0.51 % | $ 859 M | Britain |
 |
BeyondSpring
BYSI
|
$ 0.77 | 2.15 % | $ 31.7 M | USA |
 |
Cabaletta Bio
CABA
|
$ 1.92 | 0.75 % | $ 193 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 2.2 | 0.92 % | $ 3.62 M | Israel |
 |
Capricor Therapeutics
CAPR
|
$ 9.47 | 10.5 % | $ 440 M | USA |
 |
Catalyst Biosciences
CBIO
|
$ 14.59 | 1.58 % | $ 1.3 B | USA |
 |
C4 Therapeutics
CCCC
|
$ 3.33 | 6.39 % | $ 276 M | USA |
 |
Codexis
CDXS
|
$ 1.39 | 2.96 % | $ 121 M | USA |
 |
Cerus Corporation
CERS
|
$ 2.38 | 0.82 % | $ 454 M | USA |
 |
Certara
CERT
|
$ 9.2 | 0.11 % | $ 1.48 B | USA |
 |
Cullinan Management
CGEM
|
$ 15.35 | 0.79 % | $ 925 M | USA |
 |
Compugen Ltd.
CGEN
|
$ 2.38 | 1.28 % | $ 222 M | Israel |
 |
Coherus BioSciences
CHRS
|
$ 1.21 | 2.54 % | $ 142 M | USA |